Conflicts of Interest and Broad-Spectrum First-Line Antibiotic Recommendations in Community-Acquired Pneumonia Guidelines: A Meta-epidemiological Study Using the WHO AWaRe Classification.
文献摘要
Introduction This study aimed to quantify recommendation-level broad-spectrum first-line antibiotic options and explicit escalation criteria in adult community-acquired pneumonia (CAP) guidelines using the WHO AWaRe classification, and to describe findings by recommendation-relevant financial conflicts of interest (COI) and publication period. Methods We conducted a cross-sectional meta-epidemiological study of adult CAP guidelines published from 2015 to 2025 that reported development informed by a systematic review or equivalent evidence review. The analysis unit was the recommendation unit, defined as the smallest structured empiric treatment statement for a distinct clinical subgroup. The primary outcome was broad-spectrum first-line therapy, defined as inclusion of at least one WHO AWaRe Watch or Reserve antibiotic as a first-line option. Results Seven guidelines were included, providing 30 recommendation units. Of these, 19/30 (63%; 95% confidence interval [CI] 44-80%) included broad-spectrum first-line therapy, and 8/30 (27%; 95% CI 12-46%) contained explicit escalation criteria. In an exploratory descriptive comparison, broad-spectrum first-line therapy appeared more frequent in COI-present units than in COI-absent units (12/13 [92%] vs 7/17 [41%]). Broad-spectrum first-line therapy was observed in 6/8 (75%) pre-2020 units and 13/22 (59%) units published from 2020 onward. Fluoroquinolones and tetracyclines appeared more frequently in COI-present units, and drug-specific COI was most frequent for these classes. Conclusions Broad-spectrum first-line therapy was common across adult CAP guidelines, but explicit operational boundaries for broader empiric coverage were often not stated in structured recommendations. These exploratory findings warrant further investigation in larger samples.